DTIL
PRECISION BIOSCIENCES INC
Next earnings Aug 5, 2026 · consensus $-0.81 EPS, $1.15M rev
Last earnings -2.4% on 2026-05-05
$7.29
▲ +8.00%$7.29▲ +60.93%
over 1Y
L $3.57EODHDH $8.61
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+8.0%
1W+3.0%
1M-4.0%
3M+21.1%
YTD+77.8%
1Y+60.9%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.67x); but revenue fell -50.1% YoY.
Revenue (FY2025) $34.3M · FY2025
PRECISION BIOSCIENCES INC shows $34.3M in FY2025 revenue (-50.1% YoY), a -133.4% net margin, and -49.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $116M | $25.1M | $48.7M | $68.7M | $34.3M |
| Gross profit | — | — | — | — | — |
| Operating income | -$39.4M | -$62.3M | -$43.7M | -$26.2M | -$52.1M |
| Net income | -$30.6M | -$112M | -$61.3M | $7.17M | -$45.7M |
| Diluted EPS | -$0.52 | -$38.10 | -$15.96 | $1.04 | -$3.56 |
| Net margin | -26.5% | -444.8% | -125.8% | 10.4% | -133.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$91.7M
EV / EBITDA—
EV / Sales2.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-25.4%
FCF yield-36.6%
Quality & risk
ROIC (est.)-36.0%
Free cash flow-$65.9M
Total debt$22.2M
Net cash$88.6M
Altman Z-Score-3.09 distress
Piotroski F-Score1/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+135.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-102026-06-16open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗8-KPeriod ending 2026-05-272026-05-27open ↗8-KPeriod ending 2026-05-212026-05-26open ↗
Frequently asked
- Is PRECISION BIOSCIENCES INC (DTIL) a buy?
- DTIL currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.67x); but revenue fell -50.1% YoY.
- What is PRECISION BIOSCIENCES INC's quality score?
- DTIL scores 38.05882352941176/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001357874, latest 10-Q filed 2026-05-05) · EODHD · as of 6/26/2026, 7:11:20 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.